Stocks Health care SGMT
NASDAQ · Health careSagimet Biosciences Inc. (SGMT)
It posted a net loss of $47.1M. At June 30, 2026 it held $165.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Sagimet Biosciences Inc.
- Net worth
- Sagimet Biosciences Inc. has a market value (market cap) of $661.8M at the latest share price, and shareholders' equity of $256.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $2M, with a net loss of $27.9M.
- Cash flow
- In fiscal 2025 operations used $45.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sagimet Biosciences Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Sagimet Biosciences Inc. does
Sagimet Biosciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SGMT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$51M | -$1.58 | n/a |
| 2024 | n/a | -$45.6M | -$1.45 | n/a |
| 2023 | $2M | -$27.9M | -$2.66 | n/a |
| 2023 | n/a | -$30.5M | -$165.20 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Sagimet Biosciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 22, 2026
- October 7, 2026Passive stake (5% or more) SCHEDULE 13G
- October 1, 2026Material agreement8-KSagimet Biosciences agreed to raise approximately $107.5 million in net proceeds through an underwritten offering of common stock and pre-funded warrants.
- September 30, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Other event 8-K
- August 11, 2026
- August 11, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- July 21, 2026
Insider trades
What the people running Sagimet Biosciences Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 14, 2026 | Kemble GeorgeDirector | Exercised options | 326,618 | $2.1M |
| August 14, 2026 | Kemble GeorgeDirector | Exercised options | 24,369 | $155K |
| August 14, 2026 | Kemble GeorgeDirector | Soldpre-planned (10b5-1) | 350,987 | $3.6M |
| August 11, 2026 | Kemble GeorgeDirector | Exercised options | 9,751 | $62K |
| August 11, 2026 | Kemble GeorgeDirector | Exercised options | 10,455 | $66.5K |
| August 11, 2026 | Kemble GeorgeDirector | Soldpre-planned (10b5-1) | 20,206 | $201.1K |
| July 20, 2026 | Kemble GeorgeDirector | Soldpre-planned (10b5-1) | 18,844 | $140.5K |
| July 20, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Sold | 10,545 | $81.8K |
Who owns SGMT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Commodore Capital LP13G, passive with 3 related filers | 7.6% | October 7, 2026 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 5.93% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 122 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 6,575,788 | +5,775,845 |
| Balyasny Asset Management L.P. | 3,626,113 | new |
| Woodline Partners LP | 3,000,652 | +1,999,709 |
| Silverarc Capital Management, LLC | 2,927,698 | new |
| Vanguard Capital Management LLC | 2,566,272 | +1,467,353 |
| Bvf Inc | 2,500,000 | new |
| Caligan Partners LP | 2,500,000 | new |
| Affinity Asset Advisors, LLC | 2,497,864 | +1,629,844 |
| Federated Hermes, Inc. | 2,086,715 | +2,085,934 |
| Great Point Partners LLC | 2,029,933 | new |
| State Street Corp | 1,995,092 | +1,866,304 |
| Saturn V Capital Management LP | 1,479,918 | new |
| Geode Capital Management, LLC | 1,444,019 | +1,134,497 |
| Blue Owl Capital Holdings LP | 1,260,544 | +926,667 |
| Baker Bros. Advisors LP | 952,996 | 0 |
| Millennium Management LLC | 937,025 | +74,722 |
| Aberdeen Group plc | 847,700 | new |
| Goldman Sachs Group Inc | 759,086 | +589,827 |
| Hhlr Advisors, Ltd. | 724,800 | 0 |
| Ameriprise Financial Inc | 581,217 | new |
Insiders
5 insiders reported holding 1,235,129 shares in total, about $13.3M at the last price.
| Holder | Shares |
|---|---|
| Happel DavidPresident & CEO, Director | 741,570 |
| Rozek ElizabethChief Legal & Admin. Officer | 224,414 |
| Martins Eduardo BrunoChief Medical Officer | 147,296 |
| Kemble GeorgeDirector | 62,161 |
| Chauche ThierryChief Financial Officer | 59,688 |
Questions about SGMT
What does Sagimet Biosciences Inc. do?
Sagimet Biosciences Inc. is a company in the Health care sector, listed on NASDAQ as SGMT. Its shares trade on NASDAQ under the ticker SGMT.
What is Sagimet Biosciences Inc.'s net worth?
Sagimet Biosciences Inc. has a market value (market cap) of $661.8M at the latest share price, and shareholders' equity of $256.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sagimet Biosciences Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $47.1M.
When did Sagimet Biosciences Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 22, 2026.
When is Sagimet Biosciences Inc.'s next earnings report?
Sagimet Biosciences Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SGMT with
Follow SGMT
Get an email when Sagimet Biosciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sagimet Biosciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.